[Effect of immunotherapy of recombinant chimeric epitopes of major allergen group 1 from Dermatophagoides farina on asthma of mice].
To investigate the effect of immunotherapy of recombinant chimeric epitopes of major allergen group 1 from Dermatophagoides farina on asthma of mice. Forty mice were randomly divided into 4 groups: a negative control group, an asthma group, an immunotherapy group of Der f 1, and an immunotherapy group of Der f lA. On the 1st, 7th and 14th day, the mice in the asthma group, immunotherapy group of Der f 1, and immunotherapy group of Der f 1A were injected intraperitoneally with the extract of D. farina 3 times to sensitize; and on the 21st day, the atomized inhalation was carried out for 7 days. In the control group, phosphate buffer solution (PBS) was applied for sensitization and inhalation. In the immunotherapy groups, Der f 1 and Der f 1A were applied to carry out the specific immunotherapy respectively for 30 min before the inhalation. Then, the leukocytes in the bronchoalveolar lavage fluid (BALF) were numbered and the pathological sections of lung tissues were observed; IL-5 and IFN-γ in BALF and spleen cell culture supernatants (SCCS) as well as the specific IgE, IgG2a in the sera were detected. Compared with the asthma group, the lung inflammation of mice in the immunotherapy groups was lightened, and the total numbers of leukocytes in BALF were significantly reduced; IL-5 was significantly reduced and IFN-γ was significantly increased in BALF and SCCS of mice in the immunotherapy groups; and the specific IgE was significantly reduced and IgG2a was significantly increased in the sera of mice in the immunotherapy groups (all P< 0.01). The recombinant chimeric epitopes of major allergen group 1 from D. farina could effectively relieve the symptom of asthma in mice, so as to provide the evidence for specific immunotherapy.